Pancreatic cancer showdown: surgery first or chemo first?

NCT ID NCT06978322

Completed Disease control Sponsor: Minia University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This completed study looked at whether giving chemotherapy before surgery (neoadjuvant chemo) helps people with resectable pancreatic cancer live longer compared to having surgery right away. Thirty patients took part. The main goal was to see which approach leads to better overall survival and cleaner surgical margins.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chemotherapy (neoadjuvant)
What this could lead to: If chemo-first works better, it could become a new standard approach for resectable pancreatic cancer, improving survival and surgical success.
What could go wrong: This is a small, single-center trial with only 30 patients. Results may not apply broadly, and the benefit of neoadjuvant chemo is still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANAGEMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANAGEMENT NEOADJUVANT CHEMOTHERAPY RESECTABLE PANCREATIC CANCER SURGERY

Contacts and locations

Locations

Minia University

Minya, Minya Governorate, 61611, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.